From GlobeNewswire: 2025-02-08 14:30:24

4D Molecular Therapeutics announced positive interim 52-week data for 4D-150 in wet age-related macular degeneration (wet AMD) patients. The data showed an 83% reduction in injection burden compared to on-label aflibercept, with 70% requiring 0-1 supplemental injections and 57% injection-free at 52 weeks. The drug was well tolerated, with no serious adverse events reported. Durable aflibercept expression was observed in all PRISM cohorts. Clinical trials 4FRONT-1 and 4FRONT-2 are set to begin in 2025. A webcast discussing the findings will be held on February 10, 2025. 4D-150 aims to provide long-lasting treatment for vascular retinal diseases, offering potential relief from frequent injections while preserving vision.

Overall, the data from the Phase 2b Population Extension cohort of the PRISM clinical trial evaluating 4D-150 in wet AMD patients look promising. The drug showed significant reductions in injection burden compared to on-label aflibercept, with the majority of patients requiring 0-1 supplemental injections or being injection-free at 52 weeks. The drug was well tolerated, and durable aflibercept expression was observed in all cohorts. These results suggest that 4D-150 has the potential to become a new treatment option for patients with wet AMD, offering long-lasting efficacy and reduced injection frequency.

4D Molecular Therapeutics is focused on developing genetic medicines to treat diseases like wet AMD and cystic fibrosis. Their lead program, 4D-150, aims to provide sustained delivery of anti-VEGF to the retina with a single injection. The company’s Therapeutic Vector Evolution platform allows for the creation of customized vectors for different diseases, with the goal of improving patient outcomes and quality of life. Clinical trials for 4D-150 are ongoing, with promising results so far.



Read more at GlobeNewswire: 4DMT Presents Positive 52-Week Results from Phase 2b Cohort